This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Shipping:
Cold Chain Shipping
Vyloy (zolbetuximab-clzb) requires specialized “cold chain” shipping to maintain controlled temperatures and protect the medication from heat, light, and handling. Temperature-regulated boxes and vehicles ensure product integrity during transport, making cold chain delivery essential for safety and efficacy.
Disease Indications:
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma (HER2-negative, CLDN 18.2 positive)
Manufacturer:
Astellas Pharma GmbH
Usage:
Intravenous
Vyloy (zolbetuximab-clzb)
General Description:
Vyloy (zolbetuximab-clzb) is a prescription intravenous therapy for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma, whose tumors express claudin 18.2 (CLDN 18.2) positivity. Vyloy works by targeting CLDN 18.2 proteins on cancer cells, helping to inhibit tumor growth and slow disease progression.
Vyloy is administered intravenously under the supervision of a healthcare professional, with dosing determined by your oncologist based on your treatment plan and overall health.
Getting Vyloy (zolbetuximab-clzb) in India
Vyloy (zolbetuximab-clzb) is approved in the United States and European Union for the treatment of advanced gastric cancers. While not yet commercially available in India, eligible patients may access Vyloy through a Named Patient Program (NPP) with proper physician supervision.
MitoGENE helps Indian patients obtain Vyloy safely and compliantly by managing all import documentation, approvals, and logistics under India’s regulatory guidelines.
If you or a loved one has advanced or metastatic gastric cancer, MitoGENE ensures a secure, patient-centric process to access Vyloy (zolbetuximab-clzb).
Medicine Approved By:
• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Pharmaceuticals and Medical Devices Agency (PMDA, Japan)
Available Dosage Form & Package:
• Single-dose vial x 100 mg
• 3 single-dose vials x 100 mg
• Single-dose vial x 300 mg
How to Access Vyloy (zolbetuximab-clzb) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Vyloy (zolbetuximab-clzb) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
